Voyager Therapeutics, Inc. (VYGR): Total Assets
$252.28M
As of 2025-12-31
$197.75M
As of 2026-06-30
+16.5%
3-year compound annual growth
-0.7%
5-year compound annual growth
+1.0%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $252.28M | -35.8% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $393.05M | +11.9% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $351.28M | +120.4% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $159.36M | -17.8% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $193.85M | -25.9% | 2023-03-07, Balance as of period end |
| 2020-12-31 | $261.58M | -26.3% | 2022-03-08, Balance as of period end |
| 2019-12-31 | $354.76M | +100.4% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $177.03M | -4.0% | 2020-03-03, Balance as of period end |
| 2017-12-31 | $184.48M | -2.7% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $189.57M | -17.4% | 2018-03-14, Balance as of period end |
| 2015-12-31 | $229.46M | n/m | 2017-03-15, Balance as of period end |
| 2014-12-31 | $11.50M | n/a | 2016-03-17, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $252.28M | -35.8% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $186.53M | -45.4% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $59.74M | -41.2% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.74B | +78.2% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $70.55M | +57.0% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $359.07M | +2.7% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $290.46M | +98.3% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $154.42M | +13.2% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $82.35M | +12.2% |
Compare VYGR, EDIT, SGMOQ, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗